Evidence map›Paper›PMID 32468536›Full record

ArticleAdvances in experimental medicine and biology2020

Drugena: A Fully Automated Immunoinformatics Platform for the Design of Antibody-Drug Conjugates Against Neurodegenerative Diseases.

Louis Papageorgiou, Eleni Papakonstantinou, Constantinos Salis, Eleytheria Polychronidou, Marianna Hagidimitriou, Dimitris Maroulis, Elias Eliopoulos, Dimitrios Vlachakis

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Louis PapageorgiouGenetics and Computational Biology Group, Laboratory of Genetics, Department of Biotechnology, Agricultural University of Athens, Athens, Greece.
Eleni PapakonstantinouGenetics and Computational Biology Group, Laboratory of Genetics, Department of Biotechnology, Agricultural University of Athens, Athens, Greece.
Constantinos SalisGenetics and Computational Biology Group, Laboratory of Genetics, Department of Biotechnology, Agricultural University of Athens, Athens, Greece.
Eleytheria PolychronidouDepartment of Informatics, Ionian University, Corfu, Greece.
Marianna HagidimitriouGenetics and Computational Biology Group, Laboratory of Genetics, Department of Biotechnology, Agricultural University of Athens, Athens, Greece.
Dimitris MaroulisDepartment of Informatics and Telecommunications, National and Kapodistrian University of Athens, Athens, Greece.
Elias EliopoulosGenetics and Computational Biology Group, Laboratory of Genetics, Department of Biotechnology, Agricultural University of Athens, Athens, Greece.
Dimitrios VlachakisGenetics and Computational Biology Group, Laboratory of Genetics, Department of Biotechnology, Agricultural University of Athens, Athens, Greece. dimvl@aua.gr.
Agricultural University of Athens · GRNational and Kapodistrian University of Athens · GRBiomedical Research Foundation of the Academy of Athens · GRIonian University · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibodies are proteins that are the first line of defense in the adaptive immune response of vertebrates. Thereby, they are involved in a multitude of biochemical mechanisms and clinical manifestations with significant medical interest, such as autoimmunity, the regulation of infection, and cancer. An emerging field in antibody science that is of huge medicinal interest is the development of novel antibody-interacting drugs. Such entities are the antibody-drug conjugates (ADCs), which are a new type of targeted therapy, which consist of an antibody linked to a payload drug. Overall, the underlying principle of ADCs is the discerning delivery of a drug to a target, hoping to increase the potency of the original drug. Drugena suite is a pioneering platform that employs state-of-the-art computational biology methods in the fight against neurodegenerative diseases using ADCs. Drugena encompasses an up-to-date structural database of specialized antibodies for neurological disorders and the NCI database with over 96 million entities for the in silico development of ADCs. The pipeline of the Drugena suite has been divided into several steps and modules that are closely related with a synergistic fashion under a user-friendly graphical user interface.

Indexed as

Drug DesignImmunoconjugatesMedical InformaticsNeurodegenerative DiseasesAnimalsAntibodies, MonoclonalHumansNeoplasmsPharmaceutical PreparationsAntibodies, MonoclonalImmunoconjugatesPharmaceutical PreparationsComputational biologyGeneticsGenome engineeringImmunoinformaticsNeurodegenerative diseasesNeuropharmacology

Identifiers

PMID32468536
OpenAlexW3031988627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.